THIS ANNOUNCEMENT (INCLUDING THE APPENDIX) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION
Destiny Pharma plc
Result of General Meeting
and
Total Voting Rights
Destiny Pharma plc (AIM: DEST) (the "Company" or "Destiny Pharma"), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, announces that, at the General Meeting held earlier today, all resolutions proposed were duly passed by shareholders on a poll.
Accordingly, the Company has raised total gross proceeds of approximately £7.34 million from the Fundraising and has allotted a total of 20,961,956 New Shares. Admission of the Second Placing Shares, the Subscription Shares and the Open Offer Shares, is expected to occur on 17 March 2023.
Following Admission on 17 March 2023, the Company's issued ordinary share capital will comprise 94,459,061 Ordinary Shares, none of which are held in treasury. The above figure of 94,459,061 may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the voting rights of the Company under the FCA's Disclosure Guidance and Transparency Rules.
A summary of the votes received for the General Meeting will be made available on the Company's website at www.destinypharma.com.
Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the announcement of the Fundraising made by the Company on 24 February 2023.
Enquiries:
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
Optimum Strategic Communications
Mary Clark / Nick Bastin / Manel Mateus / Eleanor Cooper
+44 (0) 203 922 0891
DestinyPharma@optimumcomms.com
finnCap Ltd (Nominated Adviser and Joint Broker)
Geoff Nash / Abigail Kelly / George Dollemore, Corporate Finance
Alice Lane / Nigel Birks / Harriet Ward, ECM
+44 (0)20 7220 0500
Shore Capital (Joint Broker)
Daniel Bush / James Thomas / Lucy Bowden
+44 (0) 207 408 4090
MC Services AG
Anne Hennecke / Andreas Burckhardt
+49-211-529252-12
Stern IR - US
Janhavi Mohite
+1-212-362-1200
Janhavi.Mohite@sternir.com
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Neil Clark | ||||
| 2. | Reason for the Notification | |||||
| a) | Position/status | Chief Executive Officer | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Destiny Pharma plc | ||||
| b) | LEI | 213800O9WH9Z38EHAC95 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the Financial instrument, type of instrument | Ordinary shares of 1 pence each ("Ordinary Shares") | ||||
| Identification code | GB00BDHSP575 | |||||
| b) | Nature of the transaction | Purchase of Ordinary Shares
| ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information: Aggregated volume Price |
See 4c) above
| ||||
| e) | Date of the transaction | 16 March 2023 | ||||
| f) | Place of the transaction | London Stock Exchange, AIM Market | ||||
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Shaun Claydon | ||||
| 2. | Reason for the Notification | |||||
| a) | Position/status | Chief Financial Officer | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Destiny Pharma plc | ||||
| b) | LEI | 213800O9WH9Z38EHAC95 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the Financial instrument, type of instrument | Ordinary shares of 1 pence each ("Ordinary Shares") | ||||
| Identification code | GB00BDHSP575 | |||||
| b) | Nature of the transaction | Purchase of Ordinary Shares
| ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information: Aggregated volume Price |
See 4c) above
| ||||
| e) | Date of the transaction | 16 March 2023 | ||||
| f) | Place of the transaction | London Stock Exchange, AIM Market | ||||
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Nick Rodgers | ||||
| 2. | Reason for the Notification | |||||
| a) | Position/status | Chairman | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Destiny Pharma plc | ||||
| b) | LEI | 213800O9WH9Z38EHAC95 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the Financial instrument, type of instrument | Ordinary shares of 1 pence each ("Ordinary Shares") | ||||
| Identification code | GB00BDHSP575 | |||||
| b) | Nature of the transaction | Purchase of Ordinary Shares
| ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information: Aggregated volume Price |
See 4c) above
| ||||
| e) | Date of the transaction | 16 March 2023 | ||||
| f) | Place of the transaction | London Stock Exchange, AIM Market | ||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.